Biochemical Markers and 2 and 3D Ultrasound to ID Maternal & Fetal Complications

NCT01404221 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2015-04-14

No results posted yet for this study

Summary

Can a combination of prenatal screening blood tests, early ultrasound, and a 3D ultrasound of the fetal face at approximately 20 weeks gestation identify fetuses with congenital anomalies and predict maternal and fetal complications?

Conditions

  • Pregnancy
  • Fetal Aneuploidy

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Burton Rochelson, MD · Northwell Health

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2015-02-28
Completion
2015-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01404221 on ClinicalTrials.gov